ENDO INTERNATIONAL PLC (NASDAQ:ENDP) Files An 8-K Completion of Acquisition or Disposition of Assets
Item 2.01.Completion of Acquisition or Disposition of Assets.

On October 25, 2017, Endo International plc (the “Company”) announced the completion of the previously announced sale of all of its interests in the securities of Grupo Farmacéutico Somar, S.A.P.I. de C.V. and its subsidiaries, including their issued and outstanding ordinary shares and intercompany notes, to AI Global Investments (Netherlands) PCC Limited, acting for and on behalf of the Soar Cell (the “Purchasers”), to the terms of the purchase agreement (the “Purchase Agreement”). As previously disclosed, the Purchase Agreement was entered into on June 30, 2017, by and among the Company’s subsidiaries, Endo Somar Holdings B.V., Endo Luxembourg Finance Company I S.à r.l., Endo Global Finance LLC and Endo Luxembourg Finance Company II S.à r.l. (collectively, the “Endo Parties”), and the Purchasers. At closing, the Endo Parties received approximately $124 million in cash (after giving effect to estimated cash, debt and net working capital purchase price adjustments).

The foregoing description of the Purchase Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Purchase Agreement, attached as Exhibit 2.1 to the Company’s Quarterly Report on Form 10-Q, as filed with the SEC on August 8, 2017 and incorporated herein by reference as Exhibit 2.1.

A copy of the press release announcing the completion of the transaction is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 2.01.Financial Statements and Exhibits.

(d)Exhibits.

Endo International plc Exhibit
EX-99.1 2 exhibit991somardivestiture.htm EXHIBIT 99.1 SOMAR CLOSING PR Exhibit 99.1 Somar Divestiture PR EXHIBIT 99.1 Endo Completes Divestiture of Grupo Farmacéutico SOMAR DUBLIN,…
To view the full exhibit click here